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Abstract
Background: Squamous cell carcinoma of the head and neck (SCCHN) often contain highly radioresistant hypoxic
regions, nonetheless, radiotherapy is a common treatment modality for these tumours. Reoxygenation during
fractionated radiotherapy is desired to render these hypoxic tumour regions more radiosensitive. Hypoxia additionally
leads to up-regulation of PAI-1, a protein involved in tumour progression and an established prognostic marker for poor
outcome. However, the impact of reoxygenation and radiation on PAI-1 levels is not yet clear. Therefore, we investigated
the kinetics of PAI-1 expression and secretion after hypoxia and reoxygenation, and determined the influence of ionizing
radiation on PAI-1 levels in the two human SCCHN cell lines, BHY and FaDu.
Methods: HIF-1α immunoblot was used to visualize the degree of hypoxia in the two cell lines. Cellular PAI-1 expression
was investigated by immunofluorescence microscopy. ELISA was used to quantify relative changes in PAI-1 expression
(cell lysates) and secretion (cell culture supernatants) in response to various lengths (2 – 4 h) of hypoxic exposure (<
0.66 % O2), reoxygenation (24 h, 20 % O2), and radiation (0, 2, 5 and 10 Gy).
Results: HIF-1α expression was induced between 2 and 24 h of hypoxic exposure. Intracellular PAI-1 expression was
significantly increased in BHY and FaDu cells as early as 4 h after hypoxic exposure. A significant induction in secreted
PAI-1 was seen after 12 to 24 h (BHY) and 8 to 24 h (FaDu) hypoxia, as compared to the normoxic control. A 24 h
reoxygenation period caused significantly less PAI-1 secretion than a 24 h hypoxia period in FaDu cells. Irradiation led to
an up-regulation of PAI-1 expression and secretion in both, BHY and FaDu cells.
Conclusion: Our data suggest that both, short-term (~4 – 8 h) and long-term (~20 – 24 h) hypoxic exposure could
increase PAI-1 levels in SCCHN in vivo. Importantly, radiation itself could lead to PAI-1 up-regulation in head and neck
tumours, whereas reoxygenation of hypoxic tumour cells during fractionated radiotherapy could counteract the
increased PAI-1 levels.
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Background
The adverse effects of tumour hypoxia on the outcome
after radiotherapy are well established for many different
tumour types and in particular for SCCHN [1-4]. This is in
part due to the oxygen effect; hypoxic cells require a 2.5 to
3-fold higher radiation dose to achieve the same cell kill
seen in well-oxygenated cells. Therefore, reoxygenation of
hypoxic tumours during fractionated radiotherapy is
intended to render tumour cells more radiosensitive. In
addition, hypoxia causes a differential expression profile
which can lead to a biologically more aggressive and radi-
oresistant phenotype.
One important protein that is up-regulated under hypoxic
conditions is the plasminogen activator inhibitor type-1
(PAI-1), a multifunctional protein, best known for its role
as inhibitor of urokinase-type plasminogen activator
(uPA) [5,6]. The activated serine protease uPA is able to
convert plasminogen to plasmin, which in turn degrades
the extracellular matrix (ECM) and leads to invasion and
metastasis of tumour cells. Despite its inhibiting function
of uPA, numerous clinical studies demonstrate a strong
correlation between high tissue levels of PAI-1 and poor
prognosis for several tumour entities [7], including squa-
mous cell carcinomas of the head and neck [8,9]. This par-
adoxical finding might be explained by further biological
functions of PAI-1 in promoting migration and angiogen-
esis and in inhibiting apoptosis of tumour cells [10-13].
Previous studies have shown that both hypoxia inducible
factors, HIF-1 and HIF-2, are able to transcriptionally up-
regulate human PAI-1 via binding to the hypoxia respon-
sive element (HRE) within the PAI-1 promoter region
[14,15]. An increase in PAI-1 mRNA has been observed in
vitro as early as 2 h after hypoxic exposure in SCCHN,
human hepatoma and lung cancer cell lines [14,16,17].
Only one detailed time-course analysis of cellular PAI-1
expression levels after hypoxic exposure exists and was
performed on a single human hepatoma cell line [14].
Up-regulation of PAI-1 protein secretion by low levels of
oxygen has also been demonstrated in various human cell
lines, but so far not in SCCHN [14,16,18,19]. Further-
more, very few studies – and none on SCCHN – exist
investigating whether radiation can lead to enhanced PAI-
1 levels [20-22].
As PAI-1 is a prognostic marker for poor outcome and is
involved in tumour progression, a better understanding of
the factors (e.g., hypoxia and irradiation) responsible for
PAI-1 up-regulation in SCCHN is vital for treatment plan-
ning of patients with these especially hypoxic and radiore-
sistant tumours. Therefore, the aim of our study was first
to investigate the impact of the length of hypoxic exposure
and reoxygenation on PAI-1 expression and secretion in
the two human SCCHN cell lines, BHY and FaDu. Sec-
ondly, we examined the influence of ionizing radiation
on PAI-1 expression and secretion in these same two cell
lines.
Methods
Cell lines
The two human cell lines, BHY and FaDu, were used in
this study. BHY derives from a highly differentiated and
invasive SCC from the lower alveolus (DSMZ ACC 404)
[23] and FaDu originates from an undifferentiated
hypopharyngeal SCC (ATCC HTB-43) [24]. Cells were
cultured in Dulbecco's Modified Eagle's Medium (D-
MEM) (Invitrogen) containing 10 % foetal calf serum
(FCS), 0.05 mg/ml penicillin, 0.05 mg/ml streptomycin
and 0.1 mg/ml neomycin and maintained in a humidified
atmosphere of 95 % air and 5 % CO2 at 37°C (standard
conditions).
Hypoxic cultivation of cells
For hypoxia experiments, 5 × 105 cells were seeded into 10
cm cell culture dishes. After 72 h pre-incubation under
standard conditions, the medium was changed and the
dishes were incubated for various lengths of time (2, 4, 8,
12, 16, 20, 24 h) under normoxic (= standard conditions)
or hypoxic conditions at 37°C. To achieve hypoxic condi-
tions, dishes were placed into airtight aluminium cham-
bers connected to a vacuum pump and a N2 gas cylinder.
By alternating eleven times between oxygen evacuation
and N2 inflow, an oxygen concentration below 0.66 % (5
mm Hg) was reached after 22 min.
For reoxygenation studies, cells were removed from the
aluminium chambers after 24 h of hypoxia, then the
medium was changed and cells were cultivated for an
additional 24 h under normoxic conditions (24hH/
24hN). As a control, parallel samples were incubated for
24 h under normoxia, then the medium was changed and
cells were incubated further for 24 h under normoxic con-
ditions (24hN/24hN).
In addition, after 24 h of hypoxia, cell-free supernatants
were transferred to fresh 10 cm cell culture dishes and
incubated for 1, 2, 3 and 7 days under normoxic condi-
tions.
Trypan blue exclusion
This assay was used to determine the ratio of viable cells.
Cells cultivated 24 h under normoxia or hypoxia were
trypsinized, centrifuged, resuspended in medium, and
mixed with an equal volume of 0.4 % trypan blue staining
solution. Viable and dead cells were counted using a
haemocytometer.BMC Cancer 2007, 7:143 http://www.biomedcentral.com/1471-2407/7/143
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Irradiation
For irradiation experiments, 5 × 105 cells were seeded into
10 cm cell culture dishes. After 72 h pre-incubation under
standard conditions, the medium was changed and cells
were irradiated with 2, 5 and 10 Gy using the RT100 irra-
diation device (Philips) at a dose rate of ~1 Gy/min. Irra-
diations were performed at room temperature under
atmospheric conditions. Control cells received sham irra-
diation (= 0 Gy). After irradiation, cells were cultivated for
45 h under standard conditions.
ELISA
Supernatants of cultured cells were centrifuged to remove
debris and stored at -20°C. Attached cells were washed
twice with cold PBS and lysed in 1 × TBST buffer (0.05 M
Tris/HCl, pH 8.5, 0.1 M NaCl, 10 mM EDTA, 0.5 %
Tween20 and 0.1 % Triton X-100). The cell suspension
was rotated for 24 h at 4°C, centrifuged and the superna-
tant (= cell lysate) was stored at -20°C until further use.
Protein content in the cell lysates was determined using
the BCA™ Protein Assay Kit (Pierce). PAI-1 concentrations
in the cell lysates and supernatants were determined by
ELISA as described previously [25]. All measurements
were performed in duplicate. The mean values and stand-
ard errors of the mean (S.E.M.) were calculated from at
least three independent experiments.
For hypoxia and reoxygenation experiments, the PAI-1
antigen content in cell lysates and supernatants was calcu-
lated relative to the total protein content in the corre-
sponding cell lysate. For the calculation of relative PAI-1
levels, the PAI-1 concentrations in either cell lysates or
supernatants at 24 h normoxia were set to one.
For irradiation experiments, the PAI-1 antigen concentra-
tion in cell lysates and supernatants was calculated rela-
tive to the viable adherent cells at the time point of sample
collection. For the calculation of relative PAI-1 levels, PAI-
1 concentrations in the unirradiated samples (0 Gy) were
set to one.
Western Blot
Cell lysates (5 µg) were separated by SDS-polyacrylamide
gel electrophoresis (10 %) and blotted onto a PVDF mem-
brane. Membranes were blocked 1 h at RT with 5 % non-
fat dry milk and 0.1 % Tween-20 in PBS. Subsequently,
membranes were incubated with monoclonal anti- HIF-
1α antibody (BD Biosciences Pharmingen, 1:250) or
monoclonal anti-β-actin antibody (Sigma, 1:20000) at
4°C overnight. After washing, the blots were incubated
with secondary goat anti-mouse IgG horseradish peroxi-
dase conjugate (Promega, 1:2500) for 1 h at RT. Detection
was performed with self-made ECL (1.25 mM Luminol,
0.2 mM p-Coumaric acid, 0.09% H2O2, 100 mM Tris/HCl
pH 8.6). Cells treated with 100 µM desferrioxamine
(DFO) for 24 h under standard conditions served as posi-
tive controls.
Immunofluorescence
For immunofluorescence studies, 5 × 105  cells were
seeded onto 3-well diagnostic microscope slides (Erie Sci-
entific Company) in 10 cm cell culture dishes. After 72 h,
the medium was exchanged and cells were exposed to nor-
moxic or hypoxic conditions. Afterwards, cells were fixed
with 4 % paraformaldehyde, permeabilized with saponin
(0.025 %; 45 min at RT) and subsequently incubated in 2
% normal goat serum to block unspecific binding. Rabbit
anti-PAI-1 antibody (PAb-Rb) [25] was diluted 1:125
(FaDu) or 1:250 (BHY) in 0.1 % BSA-PBS and applied to
the slides (4°C, O/N). Cells were stained in the dark for
30 min with Alexa Fluor® 488 goat anti-rabbit IgG (Invit-
rogen) (1:400) to visualize PAI-1 and Alexa Fluor® 568
phalloidin (Invitrogen) (1:100) to visualize the cytoskele-
ton. Slides were then washed with PBS and mounted with
VECTASHIELD®  Mounting Medium containing DAPI
(Vector Laboratories). Fluorescence was observed using
an Axioskop 2 plus fluorescence microscope (Zeiss) and
the appropriate filters (Chroma Technology, BFIOptilas).
Photographic documentation was carried out using an
AxioCam MRc5 camera, an Achroplan 100 × oil objective
and the AxioVision 4.4 software (Zeiss).
Statistics
Statistical analysis was performed using SPSS 12.0.1 soft-
ware. Student's t-test was used to evaluate the differences
between normoxic, hypoxic and reoxygenated and
between unirradiated and irradiated samples (*p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001). Pearson's correlation coeffi-
cient r was used to determine linear correlations between
intracellular and secreted PAI-1 levels.
Results
Hypoxia induces HIF-1α expression
Since HIF-1α (hypoxia inducible factor-1α) expression is
known to increase after hypoxic exposure, HIF-1α was
used to validate and visualize the hypoxic induction of
cell metabolism in our system. Cells were incubated
under normoxic (24 h) or hypoxic (2, 8, 16 and 24 h) con-
ditions and cell lysates prepared. As a positive control,
cells were incubated for 24 h with 100 µM desferroxamine
(DFO) under aerobic conditions. Detection of HIF-1α by
immunoblotting shows HIF-1α expression both under
hypoxic conditions (2 – 24 h) and in DFO-treated BHY
and FaDu cells, but not under normoxic conditions (Fig.
1). HIF-1α levels increase in a time-dependent manner up
to 8 h. From 8 h to 24 h, HIF-1α levels remain nearly con-
stant. This indicates that effective intracellular hypoxia
was reached as early as 2 h after hypoxic incubation,
increased up to 8 h and was stable for at least 24 h.BMC Cancer 2007, 7:143 http://www.biomedcentral.com/1471-2407/7/143
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Influence of hypoxia on cell viability
Before examining the effects of hypoxia on PAI-1 expres-
sion by BHY and FaDu cells, it was necessary to prove
whether they could tolerate prolonged periods (24 h)
under hypoxic conditions. The counting of cells in the cell
culture supernatants revealed that 24 h hypoxia caused a
significant detachment of cells (BHY: 29.0 %; FaDu: 13.9
%) (Table 1). Additionally, since PAI-1 concentrations in
later ELISA experiments were measured in the cell lysates
of adherent cells, it was essential to prove whether 24 h of
hypoxia had an effect on the viability of the adherent cells.
The determination of viability of the trypsinized adherent
cells by the trypan blue exclusion assay demonstrated
only a slight and non-significant decrease in viability after
24 h hypoxic exposure (BHY: 97.1 %; FaDu: 98.7 %) com-
pared to normoxic conditions (BHY: 99.1 %; FaDu: 99.4
%) (Table 1).
Therefore, hypoxic exposure (24 h) causes increased
detachment of cells, but does not lead to significant loss
in cell viability of the remaining adherent cells.
Influence of hypoxia on cell morphology and PAI-1 
expression
In order to observe cell morphology and PAI-1 expression
under hypoxia, immunofluorescence studies were per-
formed. Cells were grown on slides, exposed to normoxic
or hypoxic conditions and stained with an anti-PAI-1 anti-
body (PAb-Rb) and phalloidin. Staining with phalloidin
(red) revealed no significant changes in the cytoskeleton
during hypoxic incubation (Fig. 2). PAI-1 detection by
PAb-Rb showed a strong green fluorescent signal in the
cytoplasm after 8, 16 and 24 h of hypoxia in both cell
lines, whereas the fluorescence of the normoxic control
remained weak (Fig. 2). This demonstrates that hypoxia
induces intracellular up-regulation of PAI-1 in BHY and
FaDu cells.
Kinetics of cellular PAI-1 expression under hypoxia
To investigate the kinetics of PAI-1 expression under
hypoxic conditions, BHY and FaDu cells were exposed
either to normoxia for 2 and 24 h or to hypoxia for 2, 4,
8, 12, 16, 20 and 24 h. Subsequently, the intracellular PAI-
1 levels were determined in cell lysates by ELISA. There
was no significant difference in PAI-1 expression between
2 h and 24 h of normoxic incubation in BHY and FaDu
cells. Therefore, cells incubated 24 h under normoxia were
chosen as the standard for PAI-1 expression studies and
hypoxic values were calculated relative to this value. A
detailed kinetic analysis of hypoxia revealed a time-
dependent increase in PAI-1 expression in BHY cells, start-
ing after 4 h and reaching maximal levels after 24 h of
hypoxic exposure (Fig. 3A). FaDu cells showed the same
tendency with significantly enhanced PAI-1 expression
levels after 4 h, and maximal PAI-1 expression levels after
20 h of hypoxia (Fig. 3B). The maximal relative induction
of PAI-1 is 2.0-fold for BHY after 24 h hypoxia and 3.1-
fold for FaDu after 20 h hypoxia.
Kinetics of PAI-1 secretion under hypoxia and normoxia
For the investigation of secreted PAI-1 levels, cells were
exposed to the same normoxic and hypoxic conditions as
for cellular expression studies. After 2, 4, 8, 12, 16, 20 and
24 h, PAI-1 concentrations in the cell culture supernatants
were measured. Importantly, an examination of FCS-con-
taining D-MEM medium (without cells) revealed no
detectable PAI-1.
Due to an increase in basal PAI-1 secretion levels from 2
to 24 h normoxic incubation (BHY: 5.0-fold; FaDu: 4.8-
fold), PAI-1 kinetics were studied not only under hypoxia
but also under normoxia. As shown in figure 3C and 3D,
Table 1: Viability of BHY and FaDu cells.
% detached cells % viable adherent cells
24 h N 24 h H 24 h N 24 h H
BHY 3.32 (± 0.57) 29.0 (± 2.36) *** 99.1 (± 0.35) 97.1 (± 1.24)
FaDu 0.73 (± 0.03) 13.9 (± 1.66) ** 99.4 (± 0.25) 98.7 (± 0.53)
After 24 h of normoxic or hypoxic incubation, detached cells in the supernatants and trypsinized adherent cells were counted and the percentage 
of detached cells calculated. The percentage of viable adherent cells was determined by trypan blue exclusion assay. Mean values ± S.E.M. of at least 
four independent experiments are shown. Associated significance of hypoxic vs. normoxic cells is indicated (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
HIF-1α expression in BHY and FaDu cell lysates Figure 1
HIF-1α expression in BHY and FaDu cell lysates. Cells 
were maintained under normoxia for 24 h (24hN) or hypoxia 
for 2 (2hH), 8 (8hH), 16 (16hH) and 24 h (24hH). Cells 
treated with 100 µM desferroxamine (DFO) for 24 h under 
normoxic conditions served as positive controls. 5 µg of 
each cell lysate was loaded per well and visualized on west-
ern blots using HIF-1α or β-actin antibodies as indicated.
HIF-1α α α α
β β β β-actin
BHY FaDu
24hN 2hH 8hH 16hH 24hH DFO
HIF-1α α α α
β β β β-actin
24hN 2hH 8hH 16hH 24hH DFOBMC Cancer 2007, 7:143 http://www.biomedcentral.com/1471-2407/7/143
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the amount of PAI-1 in the supernatants of both cell lines
rises with increasing lengths of both normoxic and
hypoxic exposure. A significant difference in PAI-1 secre-
tion between normoxia and hypoxia exists from 12 to 24
h for BHY and from 8 to 24 h for FaDu. The maximal dif-
ference between normoxic and hypoxic PAI-1 secretion
was seen after 20 h for both cell lines (BHY: 1.7-fold;
FaDu: 2.0-fold).
Under hypoxia, a similar time-dependent trend of intrac-
ellular (Fig. 3A and 3B) and secreted (Fig. 3C and 3D) PAI-
1 levels exists for both cell lines. Accordingly, calculation
of the Pearson's correlation coefficient, r, revealed a signif-
icant correlation between PAI-1 expression and secretion
under hypoxia for BHY (r = 0.80, p ≤ 0.05) as well as FaDu
(r = 0.91, p ≤ 0.01) cells.
Effect of reoxygenation on PAI-1 expression and secretion
First, we investigated whether secreted PAI-1 in cell cul-
ture medium is detectable by ELISA after longer incuba-
tion periods at 37°C. This was important for
reoxygenation studies, since we intended to measure only
PAI-1 that was secreted during the 24 h reoxygenation
period and not during the preceding hypoxic exposure.
For this, BHY and FaDu cells were exposed to hypoxic
conditions for 24 h. Subsequently, the supernatants were
centrifuged to remove detached cells and the cell-free
supernatants were further incubated under standard con-
ditions at 37°C. At different time points (0, 1, 2, 3 and 7
days), samples were drawn and PAI-1 concentrations in
the cell-free supernatants were determined by ELISA. The
PAI-1 levels in these cell-free supernatants remained con-
stant for up to 7 days, indicating that PAI-1 in the medium
is detectable by ELISA after prolonged incubation periods
at 37°C (Table 2).
Therefore, we decided to change the medium directly
before reoxygenation. This ensured that only newly
secreted PAI-1 protein during the 24 h reoxygenation
period was measured. Two parallel dishes were exposed to
hypoxia and two to normoxia for 24 h. Afterwards, cell
lysates and supernatants from one of the hypoxic (=
24hH) and one of the normoxic (= 24hN) dishes were
prepared or isolated, respectively. In the remaining two
dishes, the medium was changed (/indicates the medium
change) and cells were kept for an additional 24 h under
normoxic conditions (= 24hH/24hN and 24hN/24hN,
respectively). In other words, 24hH/24hN is the reoxygen-
ated sample and 24hN/24hN is the normoxic control for
medium changed dishes.
Measurements of PAI-1 concentrations in the cell lysates
of BHY and FaDu cells revealed significantly higher PAI-1
expression levels in hypoxic (24hH) and reoxygenated
(24hH/24hN) than in normoxic (24hN) cells (Fig. 4A and
4B). The PAI-1 expression in reoxygenated BHY and FaDu
cells (24hH/24hN) was slightly less compared to hypoxic
cells (24hH).
The supernatants of hypoxic BHY and FaDu cells (24hH)
also revealed significantly increased PAI-1 levels com-
pared to normoxic cells (24hN) (Fig. 4C and 4D). During
the 24 h reoxygenation period (24hH/24hN), less PAI-1
was secreted than during the 24 h hypoxic incubation
period (24hH), which was significant for FaDu cells. The
normoxic controls for the medium changed dishes
(24hN/24hN) also showed slightly less PAI-1 secretion
compared to the 24hN value, however to a lesser extent,
indicating a net reduction in PAI-1 release during reoxy-
genation. These data demonstrate that although margin-
ally more PAI-1 is secreted during reoxygenation than
under normoxia, clearly less is secreted than under
hypoxia.
Irradiation induces PAI-1 expression and secretion
To prove whether irradiation has an effect on PAI-1
expression and secretion, BHY and FaDu cells were irradi-
ated with 0, 2, 5 and 10 Gy under standard conditions.
Measurement of PAI-1 concentrations relative to the 0 Gy
control in the cell lysates and supernatants 45 h after irra-
diation showed that both, PAI-1 expression and secretion,
rises with increasing dose in both investigated cell lines
(Fig. 5). Cellular PAI-1 levels were significantly increased
after irradiation with 5 and 10 Gy in BHY cells and with 2
and 10 Gy in FaDu cells (Fig. 5A and 5B). Maximal induc-
tion of PAI-1 expression was 3.6-fold for BHY and 6.5-fold
for FaDu cells after irradiation with 10 Gy.
PAI-1 concentrations in the cell supernatants were also
enhanced 45 h after irradiation (5 and 10 Gy) (Fig. 5C and
5D), but only significantly for BHY cells. Maximal up-reg-
Influence of hypoxia on cell morphology and PAI-1 expres- sion in BHY and FaDu cells Figure 2
Influence of hypoxia on cell morphology and PAI-1 
expression in BHY and FaDu cells. Immunofluorescent 
staining with the PAI-1 antibody, PAb-Rb (BHY 1:250, FaDu 
1:125) (green), Phalloidin (red) and DAPI (blue) of BHY and 
FaDu cells grown for 24 h under normoxic (24hN) and for 8 
(8hH), 16 (16hH) and 24 h (24hH) under hypoxic conditions. 
Images of green fluorescence were consistently exposed for 
600 ms for BHY and 900 ms for FaDu.
20 µm
BHY
8hH 16hH 24hH 24hN
FaDuBMC Cancer 2007, 7:143 http://www.biomedcentral.com/1471-2407/7/143
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ulation of PAI-1 secretion was seen after irradiation with
10 Gy (BHY: 3.4-fold, FaDu: 2.3-fold).
Discussion
As PAI-1 is involved in the invasion and migration of
tumour cells and is an established marker for poor out-
come, it is crucial to investigate the exact mechanisms
leading to increased PAI-1 levels. Although previous stud-
ies have shown that both, hypoxia and irradiation are able
to up-regulate PAI-1 in different cell lines, no study has
investigated the influence of hypoxia, reoxygenation and
irradiation on PAI-1 expression and secretion in the fre-
quently hypoxic tumour entity, SCCHN. Therefore, in the
present study, we investigated the influence of these
parameters on PAI-1 expression and secretion in the two
SCCHN cell lines, BHY and FaDu. Furthermore, we ana-
lyzed in detail the kinetics of PAI-1 induction by hypoxia.
The only data available so far on hypoxia kinetics for
SCCHN cell lines is by Koong et al. [17]. However, they
only investigated one cell line (FaDu) on the transcrip-
tional and not on the protein level. They found that PAI-
1 mRNA levels were enhanced already 2 h after hypoxic
exposure and increased continuously up to 24 h.
Kinetics of PAI-1 expression and secretion under hypoxia Figure 3
Kinetics of PAI-1 expression and secretion under hypoxia. A, B: Quantitative determination of PAI-1 levels in BHY (A) 
and FaDu (B) cell lysates by ELISA. Cells incubated 24 h under normoxia were chosen as the normoxic standards for PAI-1 
expression studies and hypoxic values were calculated relative to these values (BHY: 33.5 ng/mg protein; FaDu: 8.6 ng/mg pro-
tein). Mean values ± S.E.M. of four independent experiments, each analyzed in duplicate, are shown. Associated significance of 
the hypoxic samples vs. the normoxic standard is indicated (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). C, D: Quantitative determina-
tion of PAI-1 secretion levels in cell culture supernatants from BHY (C) and FaDu (D) cells by ELISA. The PAI-1 secretion level 
after 24 h normoxia was chosen as the normoxic standard (= 1) and all other values were calculated relative to this value 
(BHY: 706.5 ng/mg protein; FaDu: 112.8 ng/mg protein). Mean values ± S.E.M. of at least four independent experiments, each 
analyzed in duplicate, are shown. Associated significance between the hypoxic sample and the corresponding normoxic sample 
(2 – 24 h) is indicated (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Concerning cellular PAI-1 protein levels, we showed sig-
nificantly increased PAI-1 levels during hypoxic exposure
between 4 and 24 h for BHY and FaDu cells (Fig. 3A and
3B). The only study describing detailed kinetics of cell-
associated PAI-1 levels under hypoxia demonstrated a
similar trend with significantly increased cellular PAI-1
levels between 8 and 48 h in the human hepatoma cell
line, HepG2 [14].
Regarding secreted PAI-1 levels, a significant difference in
PAI-1 secretion between normoxic and hypoxic cells
began after 12 (BHY) or 8 h (FaDu) of incubation and
lasted for up to 24 h (Fig. 3C and 3D). In accordance with
our results, Kimura et al. [16] demonstrated significant
up-regulation of PAI-1 secretion after 8 and up to 24 h of
hypoxic exposure for a human lung cancer cell line. Simi-
lar time-dependent studies on transformed and non-
transformed human and mouse cell lines showed signifi-
cantly elevated PAI-1 secretion levels starting between 6
and 16 h after hypoxic onset, depending on the investi-
gated cell line [14,26,27].
Taken together, these data show for SCCHN cell lines, that
PAI-1 mRNA is induced very rapidly upon hypoxic expo-
sure (2 h) [17] with a short delay in PAI-1 expression
(BHY and FaDu: 4 h) and an additional lag of some hours
in PAI-1 secretion (FaDu: 8 h; BHY: 12 h). The study by
Fink et al. [14] on the human hepatoma cell line, HepG2,
confirms these results by demonstrating a lag in PAI-1
protein synthesis behind the transcriptional up-regula-
tion. This time-lapsed hypoxic induction of PAI-1 mRNA,
cellular protein and secreted protein can be explained by
the sequence of RNA transcription, translation and secre-
tion.
Here, we report for the first time that in vitro hypoxia sig-
nificantly up-regulates cellular and secreted PAI-1 protein
levels after short exposure times (4 – 8 h) and continues
up to 24 h in two SCCHN cell lines. Additionally, we have
shown an analogous PAI-1 up-regulation by hypoxia in
both cell lines, BHY and FaDu. Therefore, our data suggest
that in vivo already short periods of hypoxia, e.g. caused by
the closure of individual capillaries or by temporary
reduction in blood flow (= acute hypoxia), might be suf-
ficient to up-regulate PAI-1 in SCCHN. Regarding radiore-
sistance, acutely hypoxic cells are believed to be a more
serious problem than chronically hypoxic cells [28].
Therefore, acute hypoxia might be harmful in two ways;
on the one hand by causing radioresistance and on the
other hand by increasing PAI-1 levels, which most likely
leads to a more aggressive phenotype of the surviving radi-
oresistant cells.
An association between high PAI-1 tumour tissue levels
and poor outcome has been observed in many clinical
studies for different tumour entities, so that PAI-1 has
become an established prognostic marker [7-9]. As PAI-1
is a secreted protein, it would be easier to measure PAI-1
levels in the plasma of patients. Therefore, we compared
PAI-1 expression and secretion levels during increasing
lengths of hypoxic exposure and found a strong correla-
tion between intracellular (Fig. 3A and 3B) and secreted
(Fig. 3C and 3D) PAI-1 levels in vitro. In vivo, no studies
exist on SCCHN, however, a clinical study on breast can-
cer patients found no correlation between PAI-1 levels in
tumour tissue and plasma [29]. The authors assume that
this discrepancy might be due to inconsistent blood sam-
pling and/or processing. Nevertheless, in a small group of
head and neck cancer patients, a relationship between
increased PAI-1 serum levels and tumour hypoxia was
detected [17]. As high amounts of PAI-1 are released from
platelets upon coagulation, PAI-1 determination in blood
plasma instead of serum probably would even have
shown greater differences between more and less hypoxic
tumours. Taken together, this suggests that PAI-1 plasma
levels might indirectly reflect the hypoxic status of a
tumour and implies that PAI-1 tumour and plasma levels
could also correlate in vivo. Therefore, in vivo studies on
SCCHN elucidating the correlation between tumour
hypoxia, PAI-1 expression in tumour tissue and PAI-1
plasma levels are promising, but should be performed
under standardized blood sampling and processing con-
ditions.
Hypoxic cells require 2.5 – 3 times the radiation dose to
produce the same level of cell kill as well-oxygenated cells.
Therefore, radiation induced reoxygenation is intended to
render hypoxic tumour cells more radiosensitive during
fractionated radiotherapy. Indeed, Suzuki et al. [30] dem-
onstrated a significantly better local control for patients
with reoxygenated cervical cancer. However, Dietz et al.
[31] showed that a higher degree of tumour reoxygena-
tion during the initial course of chemoradiation or radio-
therapy is associated with a poor outcome in head and
neck cancer patients. This phenomenon could be due to
Table 2: Detection of PAI-1 in cell-free supernatants.
PAI-1 concentration [ng/ml]
Incubation time [d] BHY FaDu
0 66.3 (± 5.9) 9.8 (± 1.9)
1 66.8 (± 6.4) 10.5 (± 2.8)
2 61.0 (± 5.5) 10.2 (± 1.8)
3 66.9 (± 4.6) 9.8 (± 2.0)
7 73.3 (± 4.3) 10.4 (± 1.8)
Cells were maintained for 24 h under hypoxic conditions, then the 
cell-free supernatants were incubated at 37°C under standard 
conditions for up to 7 days. PAI-1 concentrations [ng/ml] ± S.E.M. of 
three independent experiments, each analyzed in duplicate by ELISA 
are shown.BMC Cancer 2007, 7:143 http://www.biomedcentral.com/1471-2407/7/143
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increased levels of harmful proteins, upon reoxygenation,
e.g. proteins involved in tumour invasion and metastasis
such as PAI-1. As PAI-1 functions outside the cell, secreted
PAI-1 is especially crucial in promoting tumour progres-
sion. Most importantly, our results indicate that reoxygen-
ation leads to decreased PAI-1 secretion (Fig. 4C and 4D).
Therefore, reoxygenation seems to be favourable not only
with regard to increased radiosensitivity, but also with
regard to reduced PAI-1 levels.
We are the first to demonstrate that irradiation induces
PAI-1 expression and secretion in SCCHN cell lines (Fig.
5). Our results confirm previous in vitro studies showing
enhanced PAI-1 transcription and expression after ioniz-
ing radiation in non-transformed rat tubule epithelial
cells [21] and increased PAI-1 transcription in human
hepatoma cells [22]. In agreement with these in vitro
results, Moeller et al. [20] observed enhanced PAI-1
expression  in vivo in irradiated murine breast tumours
compared to non-irradiated tumours. As in vitro and in
vivo studies have also demonstrated HIF-1α induction by
radiation [20,32], we speculate that radiation induced
PAI-1 up-regulation might occur via HIF-1α.
Conclusion
In summary, our data suggest that both, short-term (~4 –
8 h) and long-term (~20 – 24 h) hypoxic exposure could
increase PAI-1 levels in SCCHN in vivo. Additionally, our
Effect of reoxygenation on PAI-1 expression and secretion Figure 4
Effect of reoxygenation on PAI-1 expression and secretion. PAI-1 concentrations in cell lysates (A and B) and cell cul-
ture supernatants (C and D) of BHY and FaDu cells were determined by ELISA. Two parallel dishes were exposed to hypoxic 
conditions (■ ) and two to normoxic () conditions for 24 h. Subsequently, cell lysates and supernatants from one hypoxic (= 
24hH) and one normoxic (= 24hN) dish were prepared or isolated, respectively. In the remaining two dishes, the medium was 
changed (/indicates medium change) and cells were further kept for 24 h under normoxic conditions (= 24hH/24hN and 24hN/
24hN, respectively). Mean values ± S.E.M. of at least four independent experiments, each analyzed in duplicate, are shown rel-
ative to the mean normoxic value at the time of medium change (24hN). Associated significance of each sample vs. the nor-
moxic standard (24hN) is indicated (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Additionally, the significance of the reoxygenated 
sample (24hH/24hN) vs. the hypoxic sample (24hH) is indicated in D.
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results show that not only hypoxia but also ionizing radi-
ation induces PAI-1 expression and secretion in SCCHN
cell lines. This implies that radiation therapy, which is a
common treatment modality for the frequently hypoxic
head and neck tumours, could lead to enhanced PAI-1
expression and secretion in vivo. On the other hand, reox-
ygenation of hypoxic tumour cells during fractionated
radiotherapy could be favourable by counteracting the
increased PAI-1 levels.
Therefore, future studies investigating the mechanisms
(e.g. reactive oxygen species, HIF) behind hypoxic- and
radiation-induced up-regulation of PAI-1 should help to
develop strategies (antioxidants, HIF inhibitors) to pre-
vent increased PAI-1 expression and secretion and thereby
improve the outcome after radiation therapy.
Abbreviations
DFO: desferroxamine
ECM: extracellular matrix
ELISA: enzyme-linked immunosorbent assay
HIF: hypoxia inducible factor
HRE: hypoxia responsive element
PAI-1 expression and secretion after irradiation Figure 5
PAI-1 expression and secretion after irradiation. 45 h after irradiation with 2, 5 and 10 Gy, PAI-1 concentrations in the 
cell lysates (A and B) and cell culture supernatants (C and D) of BHY and FaDu cells were determined by ELISA. Unirradiated 
cells (0 Gy) served as a control. Mean values ± S.E.M. of three independent experiments, each analyzed in duplicate, are shown 
relative to the 0 Gy mean value. Associated significance of the irradiated samples vs. the unirradiated control (0 Gy) is indicated 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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PAI-1: plasminogen activator inhibitor type-1 (PAI-1)
uPA: urokinase-type plasminogen activator
SCCHN: squamous cell carcinoma of the head and neck
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